At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 118 target
Drug / intervention
JS107 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating JS107 and Toripalimab for Advanced Solid Tumors. Targeting 118 participants across 3 sites.
Detailed Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
2023202420252026
Enrollment StartJul 2022
First PostedAug 2022
Primary CompletionJul 2024
Study CompletionDec 2024
TodayJul 2026
First PostedAug 16, 2022
Enrollment StartJul 26, 2022
Primary CompletionJul 31, 2024
Study CompletionDec 31, 2024
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 3.9 years ago
Interventions
JS107drug
JS107, i.v., q3w
Toripalimabdrug
Toripalimab i.v., q3w